Kringle Pharma, Inc. (4884.T)
- Previous Close
564.00 - Open
545.00 - Bid 545.00 x --
- Ask 555.00 x --
- Day's Range
541.00 - 571.00 - 52 Week Range
394.00 - 1,037.00 - Volume
93,900 - Avg. Volume
144,196 - Market Cap (intraday)
3.528B - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
-- - EPS (TTM)
-158.65 - Earnings Date May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.
www.kringle-pharma.comRelated News
Performance Overview: 4884.T
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4884.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4884.T
Valuation Measures
Market Cap
3.53B
Enterprise Value
1.19B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
48.64
Price/Book (mrq)
1.49
Enterprise Value/Revenue
16.82
Enterprise Value/EBITDA
-1.32
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.11%
Return on Equity (ttm)
-34.70%
Revenue (ttm)
70M
Net Income Avi to Common (ttm)
-866M
Diluted EPS (ttm)
-158.65
Balance Sheet and Cash Flow
Total Cash (mrq)
2.34B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Company Insights: 4884.T
4884.T does not have Company Insights